Skip to main content

CVRx, Inc.

CVRX
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001235912

In the last 90 days, CVRx, Inc. insiders filed 1 open-market purchase and 1 sale; 87 institutions reported holding it in 13F filings for Q2 2026, worth $78.7M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by CVRx, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $76.4K in total
Open-market sells
1 filing
1 insider, $3.34K in total
Insiders trading
1
Net value
+$73.1K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for CVRx, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for CVRx, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Binkowski BrentCHIEF OPERATING OFFICER56,514Aug 13, 20263
Dale Michael DDirector29,005Jun 3, 20261
Slattery Joseph PDirector39,365Jun 3, 20261
Nielsen Kirk G.Director8,720Jun 3, 20261
Ballinger Kevin J.Director8,720Jun 3, 20261
Jain Mudit K.Director14,370Jun 3, 20263
Hill, Mitch C.Director8,720Jun 3, 20261
Shadan MarthaDirector8,720Jun 3, 20261
Adamson Philip B.Chief Medical Officer61,578Mar 16, 20261
Morrison GregoryCHIEF HUMAN RESOURCES OFFICER34,000Mar 4, 20261
Hykes KevinPRES & CEO284,237Mar 3, 20261
Oasheim JaredCHIEF FINANCIAL OFFICER96,703Mar 3, 20261
Verrastro PaulCHIEF MKTG & STRAT OFFICER60,551Mar 3, 20261
John Robert AllenChief Revenue Officer86,036Mar 3, 20261
Johnson & Johnson10% Owner4,024,861IndirectJan 8, 20264
Johnson & Johnson Innovation - JJDC, Inc.10% Owner4,024,861IndirectJan 8, 20264
Behbahani AliDirector316Jun 7, 20240
Palmer Craig E.SVP, U.S. SALES1,229Mar 27, 20240
Yared NadimCHIEF EXECUTIVE OFFICER26,255Feb 6, 20240
Galle LizVP OF GLOBAL CLINICAL RESEARCH778Oct 18, 20230
Bruhn-Ding DeanVP OF REG. AFFAIRS AND QA54,648Aug 4, 20220
Nehra John MDirector28,266Jun 9, 20220
Brintnall JohnCHIEF STRATEGY OFFICER AND SEC21,901Apr 26, 20220
Nea Partners 10 L P10% Owner173,388IndirectJul 7, 20210
Sandell Scott D10% Owner173,388IndirectJul 7, 20210
New Enterprise Associates 10 L P10% Owner2,026,083Jul 7, 20210
GlaxoSmithKline PLC10% Owner1,007,583IndirectJul 6, 20210
Pardo Geoffrey BDirector1,829,022IndirectJul 2, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 13, 2026 (view filing)8:18 PM ETAug 13Same dayBinkowski BrentCHIEF OPERATING OFFICERPPurchase+26.2K$2.91+$76.4K+86.6%56.5K after
Aug 13, 2026 (view filing)4:26 PM ETAug 121 dayBinkowski BrentCHIEF OPERATING OFFICERSSale−1.31K$2.55−$3.34K−4.1%30.3K after10b5-1
Mar 16, 2026 (view filing)Mar 214 daysLateAdamson Philip B.Chief Medical OfficerSSale−1.26K$7.90−$9.97K−2.0%61.6K after10b5-1
Mar 3, 2026 (view filing)Mar 21 dayJohn Robert AllenChief Revenue OfficerSSale−3.96K$7.90−$31.3K−4.4%86.0K after10b5-1
Mar 3, 2026 (view filing)Mar 21 dayVerrastro PaulCHIEF MKTG & STRAT OFFICERSSale−1.28K$7.90−$10.1K−2.1%60.6K after10b5-1
Mar 3, 2026 (view filing)Mar 21 dayOasheim JaredCHIEF FINANCIAL OFFICERSSale−1.74K$7.90−$13.8K−1.8%96.7K after10b5-1
Mar 3, 2026 (view filing)Mar 21 dayHykes KevinPRES & CEOSSale−7.76K$7.90−$61.3K−2.7%284.2K after10b5-1
Feb 23, 2026 (view filing)Feb 203 daysJain Mudit K.DirectorPPurchase+46.8K$6.36+$297.6K+5.0%980.2K after
Feb 18, 2026 (view filing)Feb 18Same dayJain Mudit K.DirectorPPurchase+600$4.64+$2.78K+11.9%5.65K after
Jan 8, 2026 (view filing)4:05 PM ETNov 25-26, 202544 daysJohnson & Johnson and 1 other10% OwnerSSale−22.3K$10.03−$224.0K−0.6%4.02M afterAmended2 lots
Nov 25, 2025 (view filing)12:54 PM ETNov 21-244 daysJohnson & Johnson and 1 other10% OwnerSSale−2.70K$10.05−$27.1K−0.1%4.05M after2 lots
Nov 14, 2025 (view filing)3:07 PM ETNov 122 daysJohnson & Johnson and 1 other10% OwnerSSale−1.00K$10.00−$10.0K0.0%4.05M after
Nov 10, 2025 (view filing)3:28 PM ETNov 6-74 daysJohnson & Johnson and 1 other10% OwnerSSale−52.5K$10.21−$536.3K−1.3%4.05M after2 lots
May 19, 2025 (view filing)May 154 daysNielsen Kirk G.DirectorPPurchase+11.0K$5.45+$59.8K+0.6%1.91M after
May 14, 2025 (view filing)May 12-142 daysNielsen Kirk G.DirectorPPurchase+187.8K$5.20+$977.3K+11.0%1.90M after3 lots
May 13, 2025 (view filing)May 12-131 dayJain Mudit K.DirectorPPurchase+1.65K$4.71+$7.78K+48.5%5.05K after2 lots
May 12, 2025 (view filing)May 12Same dayHykes KevinPRES & CEOPPurchase+5.00K$4.84+$24.2K+3.9%133.0K after
Nov 21, 2024 (view filing)Nov 192 daysVerrastro PaulCHIEF MKTG & STRAT OFFICERSSale−1.43K$13.58−$19.4K−43.3%1.88K after
Aug 15, 2024 (view filing)Aug 15Same daySlattery Joseph PDirectorPPurchase+3.00K$8.10+$24.3K+10.9%30.6K after
Aug 8, 2024 (view filing)Aug 8Same daySlattery Joseph PDirectorPPurchase+3.00K$8.24+$24.7K+12.2%27.6K after
Aug 6, 2024 (view filing)Aug 6Same daySlattery Joseph PDirectorPPurchase+2.50K$9.09+$22.7K+11.3%24.6K after
Aug 5, 2024 (view filing)Aug 5Same dayHykes KevinPRES & CEOPPurchase+30.0K$8.36+$250.8KNew position30.0K after
Mar 6, 2024 (view filing)3:42 PM ETFeb 1619 daysLateJohnson & Johnson and 1 other10% OwnerSSale−3.73K$25.81−$96.1K−0.1%4.10M after
Feb 22, 2024 (view filing)Feb 202 daysVerrastro PaulCHIEF MKTG & STRAT OFFICERSSale−2.54K$21.91−$55.8K−50.9%2.46K after
Aug 7, 2023 (view filing)Aug 34 daysVerrastro PaulCHIEF MKTG & STRAT OFFICERSSale−628$18.55−$11.6K−100.0%0 after
Aug 2, 2023 (view filing)Jul 312 daysVerrastro PaulCHIEF MKTG & STRAT OFFICERSSale−1.12K$17.49−$19.6K−29.9%2.63K after
Nov 30, 2022 (view filing)Nov 282 daysVerrastro PaulCHIEF MKTG & STRAT OFFICERSSale−4.60K$11.94−$54.9K−51.1%4.40K after2 lots
May 26, 2022 (view filing)May 242 daysNielsen Kirk G.DirectorPPurchase+8.07K$5.05+$40.8K+0.5%1.71M after
May 23, 2022 (view filing)May 19-234 daysNielsen Kirk G.DirectorPPurchase+28.8K$5.04+$145.1K+1.7%1.70M after3 lots
May 5, 2022 (view filing)May 3-52 daysNielsen Kirk G.DirectorPPurchase+62.3K$6.00+$373.6K+3.9%1.67M after3 lots
May 2, 2022 (view filing)Apr 28-May 24 daysNielsen Kirk G.DirectorPPurchase+42.1K$5.97+$251.3K+2.7%1.61M after2 lots
Mar 2, 2022 (view filing)Feb 282 daysJain Mudit K.DirectorPPurchase+600$9.03+$5.42K+21.4%3.40K after
Feb 28, 2022 (view filing)Feb 244 daysNielsen Kirk G.DirectorPPurchase+3.40K$8.24+$28.0K+0.2%1.57M after
Feb 23, 2022 (view filing)Feb 18-235 daysNielsen Kirk G.DirectorPPurchase+104.9K$7.97+$835.9K+7.2%1.57M after3 lots
Nov 19, 2021 (view filing)Nov 18-191 dayJain Mudit K.DirectorPPurchase+1.18K$14.39+$16.9K+72.3%2.80K after2 lots
Aug 16, 2021 (view filing)Aug 124 daysJain Mudit K.DirectorPPurchase+625$19.72+$12.3K+62.5%1.63K after
Jul 7, 2021 (view filing)4:47 PM ETJul 25 daysNea Partners 10 L P and 1 other10% OwnerPPurchase+250.3K$18.00+$4.50MNew position173.4K after2 lots
Jul 7, 2021 (view filing)Jul 25 daysNew Enterprise Associates 10 L P10% OwnerPPurchase+225.5K$18.00+$4.06M+12.5%2.03M after
Jul 6, 2021 (view filing)Jul 24 daysGlaxoSmithKline PLC10% OwnerPPurchase+275.0K$18.00+$4.95M+37.5%1.01M after
Jul 2, 2021 (view filing)Jun 30-Jul 12 daysNehra John MDirectorPPurchase+100$26.62+$2.66KNew position100 after2 lots
Jul 2, 2021 (view filing)Jul 2Same dayNehra John MDirectorPPurchase+27.8K$18.00+$500.0K+5,680.4%28.3K after
Jul 2, 2021 (view filing)Jul 11 dayJain Mudit K.DirectorPPurchase+1.00K$25.10+$25.1KNew position1.00K after
Jul 2, 2021 (view filing)Jul 2Same dayJain Mudit K.DirectorPPurchase+222.2K$18.00+$4.00M+31.2%933.4K after
Jul 2, 2021 (view filing)Jul 2Same dayPardo Geoffrey BDirectorPPurchase+275.0K$18.00+$4.95M+17.7%1.83M after